SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-016476
Filing Date
2021-12-02
Accepted
2021-12-02 16:15:42
Documents
67
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q xlo-20210930x10q.htm   iXBRL 10-Q 2361546
2 EX-31.1 xlo-20210930xex31d1.htm EX-31.1 11969
3 EX-31.2 xlo-20210930xex31d2.htm EX-31.2 11837
4 EX-32.1 xlo-20210930xex32d1.htm EX-32.1 7960
  Complete submission text file 0001558370-21-016476.txt   7510007

Data Files

Seq Description Document Type Size
5 EX-101.SCH xlo-20210930.xsd EX-101.SCH 43242
6 EX-101.CAL xlo-20210930_cal.xml EX-101.CAL 40864
7 EX-101.DEF xlo-20210930_def.xml EX-101.DEF 173365
8 EX-101.LAB xlo-20210930_lab.xml EX-101.LAB 403457
9 EX-101.PRE xlo-20210930_pre.xml EX-101.PRE 319886
10 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20210930x10q_htm.xml XML 1223390
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

IRS No.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40925 | Film No.: 211466784
SIC: 2834 Pharmaceutical Preparations